SC
RPRX

Sophrosyne Capital’s Repros Therapeutics Inc. RPRX Stock Holding History

Sophrosyne Capital’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-93,300
Closed -$2.5M – 84
2013
Q3 		$2.5M Sell
93,300
-172,000
-65% -$3.69M 1.65% 22
2013
Q2 		$4.89M Buy
+265,300
New +$4.69M 3.84% 8

Other funds holding RPRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sophrosyne Capital's RPRX Position: Q4 2013 in Review

Sophrosyne Capital sold out of Repros Therapeutics Inc. (RPRX) in Q4 2013, closing a stake of 93,300 shares — an estimated $2.5M sold.

Sophrosyne Capital first reported a position in RPRX in Q2 2013 and held it in 2 quarters. The position peaked at $4.89M in Q2 2013. 79 funds tracked by Wall St. Rank hold RPRX as of Q4 2013.

  • Sophrosyne Capital reported no remaining Repros Therapeutics Inc. position as of Q4 2013 after selling out during the quarter.
  • Sophrosyne Capital sold 93,300 Repros Therapeutics Inc. shares in Q4 2013, an estimated $2.5M.
  • Sophrosyne Capital first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 2 quarters.
  • Sophrosyne Capital's Repros Therapeutics Inc. position peaked at $4.89M in Q2 2013.
  • 79 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2013.

Based on Sophrosyne Capital's 13F filing for Q4 2013, filed 13 Feb 2014.